New imaging technique tracks cancer drug in body
NCT ID NCT03780725
First seen Jan 19, 2026
Summary
This early-phase study tested a special PET imaging technique to see where an experimental drug (BI 754111) goes in the body and whether it reaches tumors. It involved 8 people with advanced non-small cell lung cancer or head and neck squamous cell carcinoma who also received another drug called ezabenlimab. The goal was to understand how the drug spreads, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amsterdam UMC Locatie VUMC
Amsterdam, 1081HV, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 754111 (a drug) combined with ezabenlimab (BI 754091), and a radioactive tracer ([89Zr]Zr-BI 754111) for imaging
What this could lead to
If successful, this imaging method could help doctors see which patients might benefit from this drug combination, potentially guiding more personalized treatment.
What could go wrong
This was a very small, early (Phase 1) study that was terminated early, so results are limited. It focused on imaging, not on curing or controlling the cancer, and the drug combination may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.